Related Experiment Videos
Percutaneous transluminal coronary angioplasty after non-Q-wave infarction
Insights
Percutaneous transluminal coronary angioplasty (PTCA) offers a safe and effective treatment for non-Q-wave myocardial infarction. This intervention leads to a favorable long-term prognosis with reduced angina and improved functional capacity in most patients.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Non-Q-wave myocardial infarction carries a significant risk of subsequent infarction and mortality.
- Optimal management strategies for non-Q-wave myocardial infarction require further investigation.
Purpose of the Study:
- To evaluate the safety and long-term efficacy of percutaneous transluminal coronary angioplasty (PTCA) in patients following non-Q-wave myocardial infarction.
Main Methods:
- A cohort of 52 patients with non-Q-wave myocardial infarction underwent PTCA within three months.
- Patient outcomes, including mortality, recurrent myocardial infarction, and need for reintervention, were assessed at a mean follow-up of 28 months.
- Functional status and angina symptoms were evaluated post-procedure.
Main Results:
- All 52 patients survived the follow-up period.
- Three patients experienced recurrent myocardial infarction, and nine required repeat angioplasty.
- Four patients underwent bypass surgery for recurrent symptoms, with 25% reporting angina at follow-up.
- The majority of patients demonstrated improved functional class.
Conclusions:
- Percutaneous transluminal coronary angioplasty (PTCA) is a safe therapeutic option for patients with non-Q-wave myocardial infarction.
- PTCA is associated with a favorable long-term prognosis, including reduced mortality and improved patient functional status.
Abstract:
Non-Q-wave infarction is associated with a significant incidence of infarction and death. We followed 52 patients who underwent percutaneous transluminal coronary angioplasty (PTCA) within three months of non-Q-wave myocardial infarction. Thirty-eight patients had single-vessel disease, 12 had double-vessel disease, and two had triple-vessel disease. At follow-up at 28 +/- 8 months, all patients were alive. Three suffered a recurrent myocardial infarction during the follow-up period. Nine underwent repeat angioplasty. Four patients had bypass surgery for recurrent symptoms. Only 25% of the patients had angina at follow-up, and all but two were in an improved functional class. PTCA may be used safely in the management of patients after non-Q-wave infarction and results in a favorable long-term prognosis.